神经病理性角膜疼痛:管理方法
本文为综述,系统检索1966年至2017年相关文献,提出神经病理性角膜疼痛(NCP)的诊断与分型算法及分层治疗推荐,推荐部分基于方法学可靠的随机对照试验(RCT)及作者十余年管理经验。一线局部治疗为神经再生与抗炎药物,一线全身药物为三环类抗抑郁药与一种抗惊厥药,二线口服包括一种阿片受体拮抗剂与阿片类镇痛药。作者指出迫切需要长期研究与RCT评估NCP治疗疗效。
要点
- 推荐一线局部治疗为神经再生和抗炎药物,一线全身用药为三环类抗抑郁药和一种抗惊厥药。
- 二线口服治疗推荐一种阿片受体拮抗剂和阿片类镇痛药。
- 心血管运动、针灸、omega-3脂肪酸补充和无麸质饮食等辅助治疗可能有额外获益。
核心结论
- NCP目前是一种定义不明确的疾病,患者管理极具挑战,循证临床推荐稀缺。
- 作者提出基于临床评估与辅助检查的综合算法用于NCP诊断与亚型分类,并给出分层治疗推荐。
- 作者指出迫切需要长期研究和RCT评估NCP治疗疗效。
研究设计与样本
- 综述:对1966年至2017年间所有相关出版物进行系统文献检索。
- 治疗推荐部分基于方法学可靠的RCT(显示优于安慰剂或相关对照治疗)、证据一致性、疗效程度和安全性,并纳入作者过去十年管理此类患者的自身经验。
主要发现
- NCP由神经系统原发病灶或功能障碍引起,可发生于角膜。
- 推荐的一线局部治疗包括神经再生和抗炎药物。
- 推荐的一线全身药物治疗包括三环类抗抑郁药和一种抗惊厥药。
- 推荐的二线口服治疗包括一种阿片受体拮抗剂和阿片类镇痛药。
- 心血管运动、针灸、omega-3脂肪酸补充和无麸质饮食等补充与替代治疗可能有额外获益;难治性病例中潜在的无创和有创操作同样可能有额外获益。
关键数值与推荐
- 一线局部治疗:神经再生和抗炎药物。
- 一线全身药物治疗:三环类抗抑郁药和一种抗惊厥药。
- 二线口服治疗:一种阿片受体拮抗剂和阿片类镇痛药。
- 补充与替代治疗:心血管运动、针灸、omega-3脂肪酸补充、无麸质饮食,可能有额外获益。
- 难治性病例:潜在的无创和有创操作可能有额外获益。
临床怎么用
- 作者提出基于临床评估和辅助检查的算法用于NCP诊断与亚型分类。
- 作者推荐按一线、二线分层选择局部、全身及口服治疗,并个体化定制用药,考虑副作用、合并症及外周和中枢性疼痛水平。
- 作者提出补充与替代治疗可能有额外获益,难治性病例中潜在的无创和有创操作可能有额外获益。
局限性
- NCP目前是一种定义不明确的疾病。
- NCP患者管理极具挑战,循证临床推荐稀缺。
- 作者指出迫切需要长期研究和RCT评估NCP治疗疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neuropathic pain is caused by a primary lesion or dysfunction of the nervous system and can occur in the cornea. However, neuropathic corneal pain (NCP) is currently an ill-defined disease. Patients with NCP are extremely challenging to manage, and evidence-based clinical recommendations for the management of patients with NCP are scarce. The objectives of this review are to provide guidelines for diagnosis and treatment of patients with NCP and to summarize current evidence-based literature in this area. We performed a systematic literature search of all relevant publications between 1966 and 2017. Treatment recommendations are, in part, based on methodologically sound randomized controlled trials (RCTs), demonstrating superiority to placebo or relevant control treatments, and on the consistency of evidence, degree of efficacy, and safety. In addition, the recommendations include our own extensive experience in the management of these patients over the past decade. A comprehensive algorithm, based on clinical evaluation and complementary tests, is presented for diagnosis and subcategorization of patients with NCP. Recommended first-line topical treatments include neuroregenerative and anti-inflammatory agents, and first-line systemic pharmacotherapy includes tricyclic antidepressants and an anticonvulsant. Second-line oral treatments recommended include an opioid-antagonist and opiate analgesics. Complementary and alternative treatments, such as cardiovascular exercise, acupuncture, omega-3 fatty acid supplementation, and gluten-free diet, may have additional benefits, as do potential noninvasive and invasive procedures in recalcitrant cases. Medication selection should be tailored on an individual basis, considering side effects, comorbidities, and levels of peripheral and centralized pain. Nevertheless, there is an urgent need for long-term studies and RCTs assessing the efficacy of treatments for NCP.
引用
- Dieckmann G, Goyal S, Hamrah P, et al. Neuropathic Corneal Pain: Approaches for Management. Ophthalmology. 2017. PMID: 29055360. doi:10.1016/j.ophtha.2017.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。